Targeted metabolomic analysis of nitric oxide/L-arginine pathway metabolites in dementia: Association with pathology, severity, and structural brain changes
MG Fleszar, J Wiśniewski, M Zboch, D Diakowska… - Scientific Reports, 2019 - nature.com
L-Arginine/NO pathway is altered in Alzheimer disease (AD). Its clinical relevance and
pathway status in vascular dementia (VaD) are unknown. Using targeted metabolomics (a …
pathway status in vascular dementia (VaD) are unknown. Using targeted metabolomics (a …
[PDF][PDF] Mariusz G. fleszar, Jerzy Wiśniewski1, Marzena Zboch3, Dorota Diakowska4
A Gamian, M Krzystek-Korpacka - 2020 - ppm.umw.edu.pl
L-Arginine/no pathway is altered in Alzheimer disease (AD). its clinical relevance and
pathway status in vascular dementia (VaD) are unknown. Using targeted metabolomics (a …
pathway status in vascular dementia (VaD) are unknown. Using targeted metabolomics (a …